How Testosterone Cypionate Affects Your Lipid Panel

HDL Cholesterol: The Most Consistent Change

The best-documented lipid shift during testosterone cypionate therapy is a reduction in high-density lipoprotein cholesterol. Across multiple randomized controlled trials, HDL falls by approximately 2 to 5 mg/dL within the first 3 to 6 months of treatment at replacement doses (100 to 200 mg every 1 to 2 weeks) 1.

This decline is dose-dependent. A 2017 meta-analysis of 59 RCTs (N=5,082) by Corona et al. found that intramuscular testosterone reduced HDL by a weighted mean of 3.8 mg/dL (95% CI: 2.1 to 5.4) compared with placebo 2. Men receiving higher doses saw larger drops. In studies using supraphysiological doses above 300 mg per week, HDL fell by 8 to 13 mg/dL, a degree that moves many men below the 40 mg/dL threshold considered protective against cardiovascular disease 3.

The mechanism is hepatic lipase upregulation. Testosterone increases hepatic lipase activity, which accelerates HDL particle catabolism and clearance from plasma 4. This is a pharmacodynamic effect that tracks circulating androgen levels. Because intramuscular testosterone cypionate produces a peak roughly 48 to 72 hours after injection followed by a trough before the next dose, hepatic lipase activity fluctuates in parallel.

One partial counterbalance exists. Testosterone aromatizes to estradiol, and estradiol stimulates hepatic apolipoprotein A-I production, which supports HDL assembly. Men who aromatize more (often those with higher body fat) may see a smaller net HDL reduction. Conversely, men co-administered aromatase inhibitors like anastrozole lose this protective offset and experience steeper HDL drops 5.

LDL Cholesterol: Variable and Dose-Dependent

Unlike the consistent HDL decline, LDL changes during testosterone cypionate therapy are heterogeneous. Some trials report a small decrease, others a small increase, and many show no statistically significant change at replacement doses.

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials in 788 men aged 65 and older with serum testosterone below 275 ng/dL, examined multiple endpoints including cardiovascular markers. In the cardiovascular substudy, testosterone gel (not cypionate, but the androgen-receptor pharmacodynamics are identical once absorbed) was associated with an increase in coronary artery plaque volume on CT angiography, though lipid subfraction changes were modest and not a primary driver of this finding 6.

The Fernández-Balsells meta-analysis of 51 trials found no significant overall change in LDL across testosterone formulations (weighted mean difference: +1.2 mg/dL; 95% CI: -3.1 to +5.5) 1. The Corona 2017 update confirmed this pattern 2. What the pooled data obscure is that men with significant baseline insulin resistance sometimes show LDL improvement as visceral adiposity decreases and insulin sensitivity improves, while lean men with already-normal lipids see little movement.

For clinical purposes, expect LDL to remain within 5 to 10 mg/dL of baseline at standard doses. Any shift larger than 15 mg/dL should prompt investigation of confounders: diet change, statin adherence, thyroid dysfunction, or a dose that has pushed testosterone levels supraphysiological.

Total Cholesterol: A Modest Net Decline

Total cholesterol typically decreases by 5 to 15 mg/dL in hypogonadal men starting testosterone cypionate, driven primarily by reductions in VLDL and, in some cohorts, LDL fractions 2.

This is not paradoxical despite the HDL drop. Hypogonadism is itself associated with an atherogenic lipid profile: elevated triglycerides, elevated VLDL, and sometimes elevated total cholesterol. Restoring testosterone to the physiologic range (400 to 700 ng/dL trough) improves body composition, reduces visceral fat mass, and enhances insulin sensitivity, all of which push total cholesterol downward 7.

The net cardiovascular implication depends on which fractions are changing. A total cholesterol drop of 10 mg/dL that comes entirely from VLDL, paired with an HDL drop of 4 mg/dL, leaves the TC:HDL ratio roughly unchanged or slightly worse. Clinicians should track individual fractions rather than total cholesterol alone. The 2018 Endocrine Society Clinical Practice Guideline states: "We recommend measuring a fasting lipid panel at baseline and at 6 to 12 months after starting testosterone therapy" 8.

Triglycerides: Improvement in Metabolic Syndrome

Triglyceride levels tend to decline modestly during testosterone cypionate therapy, with the largest reductions seen in men who have baseline metabolic syndrome or triglycerides above 150 mg/dL.

Corona et al. reported a pooled triglyceride reduction of 15.6 mg/dL (95% CI: 7.4 to 23.8) across RCTs, a statistically significant effect that reached clinical relevance in men with elevated starting values 2. A large registry study by Saad et al. followed 823 hypogonadal men on testosterone undecanoate (mechanistically equivalent to cypionate at steady state) for up to 12 years. Triglycerides fell from a mean of 252 mg/dL to 196 mg/dL, a 22% reduction sustained over the observation period 9.

The mechanism is improved insulin sensitivity and reduced hepatic lipogenesis. Testosterone suppresses lipoprotein lipase in abdominal adipose tissue while promoting fatty acid oxidation in skeletal muscle, shifting substrate utilization away from triglyceride storage 10. Men who are lean at baseline with triglycerides already below 100 mg/dL rarely see meaningful additional reductions.

The TRAVERSE Trial and Cardiovascular Safety

The biggest question surrounding TRT and lipids is whether the HDL decline translates to increased heart attacks or strokes. Short answer: it does not appear to, based on the largest cardiovascular safety trial ever conducted for testosterone.

TRAVERSE (Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE) randomized 5,246 men aged 45 to 80 with hypogonadism and pre-existing or high risk for cardiovascular disease to transdermal testosterone or placebo. Over a mean follow-up of 33 months, the primary composite endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) occurred in 7.0% of the testosterone group versus 7.3% of the placebo group (HR 0.96; 95% CI: 0.78 to 1.17) 11.

Dr. Shalender Bhasin, the principal investigator, stated: "These results provide reassurance that testosterone replacement therapy in middle-aged and older men with hypogonadism and cardiovascular risk factors does not increase the incidence of major adverse cardiovascular events" 11.

TRAVERSE did identify a higher incidence of atrial fibrillation and acute kidney injury in the testosterone arm, but lipid-related atherosclerotic events were not increased. This suggests that the modest HDL reduction observed with TRT is either too small to alter plaque progression meaningfully or is offset by other metabolic improvements (reduced visceral fat, improved glycemic control, decreased inflammatory markers).

Supraphysiological Doses: A Different Risk Profile

The reassuring TRAVERSE data apply to replacement-dose therapy. Men using testosterone cypionate at bodybuilding doses (400 to 600 mg per week, sometimes higher) face a qualitatively different lipid profile.

At supraphysiological levels, HDL can fall below 20 mg/dL. A study by Thompson et al. in strength athletes using self-reported anabolic steroid regimens documented mean HDL values of 26 mg/dL, compared with 55 mg/dL in non-using controls 3. LDL may simultaneously rise by 20 to 30 mg/dL, partly driven by increased hepatic cholesterol synthesis and partly by the addition of oral 17-alpha-alkylated steroids that suppress HDL through first-pass hepatotoxicity.

Co-administration of aromatase inhibitors at these doses compounds the problem. Without estradiol-mediated apoA-I production, HDL particle assembly is further impaired. This combination, high-dose testosterone plus aromatase inhibitor, produces the most severely atherogenic lipid phenotype observed in TRT populations.

The clinical implication is clear. Lipid monitoring every 3 months is appropriate for any patient on doses exceeding 200 mg per week, and prescribers should address supraphysiological trough levels promptly.

Route of Administration Matters

Intramuscular testosterone cypionate produces pharmacokinetic peaks and troughs that differ from transdermal gels or subcutaneous pellets. These swings influence lipid dynamics.

Peak serum testosterone after an intramuscular injection of 200 mg testosterone cypionate reaches approximately 1,200 to 1 to 500 ng/dL at 48 to 72 hours, then declines to 300 to 500 ng/dL by day 14 12. During peak periods, hepatic lipase activity surges, HDL clearance accelerates, and SHBG is suppressed. During trough periods, these effects attenuate. The net result is slightly greater average HDL suppression compared with transdermal testosterone at equivalent steady-state levels.

The 2018 Endocrine Society guideline acknowledges this, noting: "Injectable testosterone esters result in wider fluctuations in serum testosterone levels than do transdermal preparations" 8. Splitting the injection frequency (e.g., 100 mg weekly instead of 200 mg biweekly) reduces peak-to-trough variability and may attenuate HDL suppression, though no head-to-head RCT has confirmed this for lipid outcomes specifically.

Subcutaneous injection of testosterone cypionate, increasingly used in clinical practice, produces more stable levels similar to transdermal preparations and may offer a lipid-friendlier pharmacokinetic profile at the same total weekly dose 13.

Monitoring Schedule and Clinical Action Steps

The Endocrine Society 2018 guideline provides a clear monitoring framework for men on testosterone cypionate 8.

Baseline: Obtain a fasting lipid panel before starting therapy. This serves as the comparator for all future values. Document any pre-existing dyslipidemia, statin use, or familial hypercholesterolemia history.

3 to 6 months: Repeat the fasting lipid panel. Most HDL changes are detectable by this point. If HDL has dropped below 40 mg/dL or LDL has risen above the patient's ASCVD-risk-appropriate threshold, consider dose adjustment, injection frequency change, or addition of lipid-lowering therapy.

Annually thereafter: Repeat the fasting lipid panel at each annual visit. Stable patients on consistent doses rarely show progressive lipid deterioration beyond the initial 6-month adjustment period.

Special situations: Men with baseline ASCVD, familial hypercholesterolemia, or metabolic syndrome warrant lipid checks every 3 to 6 months for the first 2 years. Men whose testosterone trough levels exceed 900 ng/dL on routine monitoring should have their dose reduced and lipids rechecked at the new steady state.

Statin therapy is not contraindicated during TRT. For men who meet ACC/AHA statin eligibility criteria independent of their testosterone use, statin initiation should follow standard guidelines. The HDL reduction from TRT does not alter statin benefit calculations because statins work primarily through LDL reduction and anti-inflammatory pathways, not HDL elevation 14.

Who Needs Extra Caution

Not all men on testosterone cypionate face equal lipid risk. Several populations warrant heightened vigilance.

Men over 65 carry higher baseline ASCVD risk. The TTrials coronary-artery plaque finding, while not driven by lipid changes alone, suggests that older men with subclinical atherosclerosis may be more susceptible to any adverse lipid shift 6. Shared decision-making and cardiologist involvement are appropriate for this group.

Men with familial hypercholesterolemia have LDL-receptor dysfunction that makes any incremental LDL increase clinically significant. Even the modest and inconsistent LDL changes seen with TRT could push these patients further from goal.

Men using concurrent aromatase inhibitors lose the estradiol-mediated HDL protection described earlier. If an aromatase inhibitor is clinically indicated (e.g., for gynecomastia management), lipid monitoring should intensify to every 3 months.

Men on supraphysiological doses, whether prescribed or self-administered, require the most aggressive monitoring. The lipid phenotype at these doses resembles that of anabolic steroid abuse, with HDL values that can drop below 25 mg/dL and create meaningful short-term atherogenic risk 3.

A practical starting point for all patients: obtain the baseline lipid panel at the same visit you draw the confirmatory morning testosterone level, then repeat both at 3 months on a stable dose 8.